Biora Therapeutics, Inc. Share Price

Equities

BIOR

US74319F3055

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
0.6277 USD +3.41% Intraday chart for Biora Therapeutics, Inc. +2.07% -53.50%
Sales 2024 * 3K 240K Sales 2025 * 2.5M 200M Capitalization 22.52M 1.8B
Net income 2024 * -68M -5.44B Net income 2025 * -77M -6.16B EV / Sales 2024 * 7,508 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 9 x
P/E ratio 2024 *
-0.43 x
P/E ratio 2025 *
-0.49 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 106.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.41%
1 week+2.07%
Current month-42.94%
1 month-46.35%
3 months-33.22%
6 months-67.81%
Current year-53.50%
More quotes
1 week
0.59
Extreme 0.5928
0.66
1 month
0.59
Extreme 0.585
0.82
Current year
0.59
Extreme 0.585
1.99
1 year
0.59
Extreme 0.585
6.70
3 years
0.59
Extreme 0.585
155.00
5 years
0.59
Extreme 0.585
398.00
10 years
0.59
Extreme 0.585
398.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 07/11/21
Director of Finance/CFO 56 30/04/19
Chief Tech/Sci/R&D Officer - 30/04/23
Members of the board TitleAgeSince
Director/Board Member 49 31/05/14
Chairman 61 31/12/18
Chief Executive Officer 57 07/11/21
More insiders
Date Price Change Volume
26/04/24 0.6277 +3.41% 133,686
25/04/24 0.607 -2.08% 151,521
24/04/24 0.6199 -2.99% 184,411
23/04/24 0.639 +5.43% 383,304
22/04/24 0.6061 -1.45% 160,218

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6277 USD
Average target price
10.3 USD
Spread / Average Target
+1,540.91%
Consensus